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JOURNAL OF HEPATOLOGYTo the Editor:
We thank Dr. Bitetto et al. for their interest in our study recently
published in the Journal of Hepatology [1]. In this study, we
reported a high prevalence of severe vitamin D deﬁciency in
patients with chronic hepatitis C, even in the absence of signiﬁ-
cant liver ﬁbrosis. We found that vitamin D deﬁciency was asso-
ciated with failure to achieve a sustained virologic response (SVR)
to therapy of chronic hepatitis C with pegylated interferon-alfa
and ribavirin. Bitetto et al. have now accentuated the important
question, whether vitamin D deﬁciency is caused by hepatitis C
virus (HCV) infection, or whether vitamin D deﬁciency may
confer an enhanced susceptibility to chronic HCV infection. We
believe that this question cannot be ﬁnally answered at the
moment. In our study, we reported a slight increase of
25-hydroxyvitamin D serum levels from baseline to week 24 after
completion of antiviral therapy in those patients who achieved a
SVR. As highlighted by Bitetto et al. and others [2,3], we have
made an attempt to stratify the patients included in this
sub-analysis according to the season in which serum samples
for vitamin D measurement were taken. In detail, 50% of patients
started therapy in winter/spring and SVR was ascertained in
summer/autumn, which was vice versa in the remaining 50% of
patients. Meanwhile, we have also re-analyzed our complete
cohort according to the season when baseline serum samples
for vitamin D detection were taken. Although we observed
slightly lower baseline 25-hydroxyvitamin D serum levels in
patients who started therapy in winter/spring compared to sum-
mer/autumn (mean 16.6 and 18.7 ng/ml, p = 0.054), severe vita-
min D deﬁciency (<10 ng/ml) was associated with chronic HCV
infection during all seasons (26% vs. 19% in winter/spring vs. sum-
mer/autumn, respectively, compared to 20% vs. 6% in winter/
spring vs. summer/autumn samples in our non-HCV infected con-
trol group). In addition, season had no signiﬁcant inﬂuence on
SVR rates. Nevertheless, we fully agree with Bitetto et al. that
our observations do not prove that HCV infection itself can cause
vitamin D deﬁciency. In addition to a residual season inﬂuence,
factors such as changes in life-style or eating habits may contrib-Tips for portal vein thrombosis
unblockin
To the Editor:
Han et al. recently published a case series of patients with cirrhosis
whohaddevelopedportalandsplanchnicvein thrombosis atvarious
intervals from treatment with transjugular intrahepatic portosys-
Journal of Hepatology 20ute to the increase of vitamin D serum levels after successful HCV
eradication. To resolve the ‘‘what comes ﬁrst’’ question results of
basic research on a potential interplay between HCV infection
and vitamin D metabolism, as well as additional clinical data
from large and well deﬁned patient cohorts are required.
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temic shunt (TIPS), for complications of the resulting portal hyper-
tension [1]. We are pleased that they conﬁrmed our published
ﬁndings that TIPS is feasible and effective in patients with PVT,
including thosewithcavernous transformationof theportal vein [2].
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They also reported predictive factors related to the technical fea-
sibility of TIPS, suggesting that only inpatientswith complete occlu-
sion of themain portal vein andﬁne collaterals at the hepatic hilum,
was TIPS not worthwhile, because of a high risk of failure. Although
the present study has the largest series of patientswith cirrhosis and
PVT assessed for TIPS, we feel there are some important issues that
deserve comment, to maintain a balanced and objective view.
First, although patients were classiﬁed according to a deﬁni-
tion of acute or chronic thrombosis (which included the presence
of an established cavernoma in 30 of 57 patients), an estimation
of the age of the thrombus before TIPS was not reported, and
moreover, in the table, all patients were deﬁned as chronic,
despite the authors statement that a cavernoma was not consid-
ered as a clear sign of long standing thrombosis.
Second, 70% of patients had an extension of thrombosis into
the splanchnic vessels: 79% having splenic vein thrombosis
(SVT) and 75% mesenteric vein thrombosis (SMVT) and 53%
cavernomas. Somewhat surprisingly, the authors managed to
completely repermeate all the thrombosed vessels in all patients
in whom TIPS was placed. This is quite exceptional, in addition to
the fact that this result was obtained solely by using angioplasty.
Third, if a complete repermeation of the splanchnic vessels
could not be accomplished by angioplasty, this was an indication
to abandon the procedure, because of a presumed high risk of
shunt failure if a TIPS was to be placed. A ﬁrm recommendation
was given to place stents in the SMV if there was residual throm-
bus in the SMV.
Ourpublishedandsubsequent experience contradicts theseaspects
[2]. A complete thrombosis of the main portal vein should not be con-
sidered a contraindication to TIPS providing the intrahepatic branches
are visible, as a direct puncture can be performed by the tranjugular
route. Indeed in our series, patency of intrahepatic portal branches
was the only signiﬁcant predictor of technical success of TIPS, even
whentherewascavernomatoustransformationof theportalvein.Tran-
shepatic puncture cannot be performed and is risky if the intrahepatic
branchesof theportal vein are thrombosed, anda transplenic approach
is also risky and unlikely to succeed.
We found that mechanical disruption of the thrombus is not
always feasible (especially so with only angioplasty), particularly
in patients with long standing thrombosis. However, when
thrombectomy could not be accomplished in all thrombosed
splanchnic vessels, restoring portal ﬂow with placement of TIPS,
together with anticoagulation, allowed repermeation of some
vessels in the long term.
When we evaluated together, both our published series of PVT
in cirrhosis [2], and patients enrolled in a prospective protocol of
treatment of PVT [3], we had 25 patients: 17 males, mean age
48 years (range 17–65), alcohol related cirrhosis in 11 patients,
Child class A/B/C were 14/12/9. Fourteen patients had complete
PVT with extension into SMV in 8, and SV alone in 5 cases, and
6 had cavernomas. The indication for attempt at TIPS placement
was: emergency for variceal bleeding in 7, recurrent bleeding in
6, ascites in 4, and treatment of progressive PVT despite anticoag-
ulation in 7. TIPS was successfully placed in 20/25 patients (80%).
No transhepatic approach was attempted and we here conﬁrmed
that the absence of visible intrahepatic branches was the only fac-
tor signiﬁcantly correlated with the risk of failure for TIPS place-
ment: 5/5 failure group versus 1/20 success group (p <0.001).
Another difference in our series is that despite thrombectomy
only being feasible in 58%, the restored ﬂow in the portal vein
(although only partial in some cases) resulted in the absence of
bleeding episodes during follow up, with a similar rate of stent
dysfunction reported by Han et al. (22% and 33% at 1 and 2 year,
respectively). Notably, in one patient of our series with long
standing thrombosis in portal, superior mesenteric, and splenic
veins, who had emergency TIPS for bleeding duodenal varices
and developed TIPS occlusion, anticoagulation resulted in com-
plete repermeation of all the splanchnic vessels, even though
the TIPS remained thrombosed.
It is important to note that we never extended the TIPS stent
into the SMV. As PVT occurs more frequently in patients with
advanced liver disease who are more likely to be candidates for
liver transplantation, the extension of the stent distally into the
extrahepatic main trunk of the portal vein or into the SMV can
jeopardize the transplant surgery [4].
Both our series and the one from China clearly establish that
TIPS is feasible in extensive splanchnic thrombosis to treat portal
hypertensive complications. However, we believe the role of TIPS
needs redeﬁning: it should be considered in all patients with cir-
rhosis and PVT, who are candidates for liver transplantation,
whenever anticoagulation is contraindicated, or if there is pro-
gression of thrombosis despite anticoagulation – this will result
in repermeation and patency of the portal vein, in a large propor-
tion of patients [5]. This should facilitate surgery and decrease
morbidity and mortality after transplantation.
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